BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue

Reuters

30 Apr

BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue

April 30 (Reuters) - Surmodics Inc SRDX.O:

SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE
SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS
SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES
SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY

Further company coverage: SRDX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2531903305"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531903305\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531903305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531903305","market":"us","top_or_hot":-1,"title":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Surmodics Inc <span>SRDX.O</span>:</p><ul><li><p>SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE</p></li><li><p>SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS</p></li><li><p>SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES</p></li><li><p>SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY</p></li></ul><p>Further company coverage: <span>SRDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-30 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product Revenue</title></head><body><p><span>April 30 (Reuters)</span><span> - </span>Surmodics Inc <span>SRDX.O</span>:</p><ul><li><p>SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUE</p></li><li><p>SURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTS</p></li><li><p>SURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALES</p></li><li><p>SURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFY</p></li></ul><p>Further company coverage: <span>SRDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SRDX","symbol_name":"SurModics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81YC:1","article_id":"2531903305","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531903305","pubTimestamp":1746012381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product RevenueApril 30  - Surmodics Inc SRDX.O:SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUESURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTSSURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALESSURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFYFurther company coverage: SRDX.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SRDX":"SurModics"},"translate_title":"简介-Surmodics预计2025财年财务业绩仍将受到Surveil DCB许可费和产品收入下降的影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRDX":0.9},"content_text":"BRIEF-Surmodics Expects FY25 Financial Performance To Remain Impacted By Lower Surveil DCB License Fee, Product RevenueApril 30 (Reuters) - Surmodics Inc SRDX.O:SURMODICS EXPECTS FY25 FINANCIAL PERFORMANCE TO REMAIN IMPACTED BY LOWER SURVEIL DCB LICENSE FEE, PRODUCT REVENUESURMODICS EXPECTS FY25 FINANCIAL GUIDANCE DOES NOT REFLECT POSSIBLE TARIFF IMPACTSSURMODICS TARIFF EXPOSURE RELATED TO SUPPLY CHAIN REPRESENTS MODEST PERCENTAGE OF TOTAL PRODUCT SALESSURMODICS TARIFF EXPOSURE FROM CUSTOMER MEDICAL DEVICE AND TEST KIT SALES IS DIFFICULT TO QUANTIFYFurther company coverage: SRDX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}